Insulin glargine and lixisenatide Subcutaneous and Omidria
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and Omidria and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: ketorolac / phenylephrine ophthalmic
Brand name: Omidria
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Omidria Ophthalmic
- Insulin glargine and lixisenatide Subcutaneous-Omnaris
- Insulin glargine and lixisenatide Subcutaneous-Omnaris eent
- Insulin glargine and lixisenatide Subcutaneous-Omnicef
- Insulin glargine and lixisenatide Subcutaneous-Omnicef (Cefdinir Capsules)
- Insulin glargine and lixisenatide Subcutaneous-Omnicef (Cefdinir Suspension)
- Omidria-Insulin glargine, recombinant Subcutaneous
- Omidria-Insulin glulisine
- Omidria-Insulin Glulisine (Cartridges and Pens)
- Omidria-Insulin Glulisine (Vials)
- Omidria-Insulin glulisine Subcutaneous
- Omidria-Insulin human inhaled Inhalation